{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06001658",
            "orgStudyIdInfo": {
                "id": "J2390"
            },
            "secondaryIdInfos": [
                {
                    "id": "IRB00371087",
                    "type": "OTHER",
                    "domain": "Johns Hopkins Medicine Internal Review Board"
                }
            ],
            "organization": {
                "fullName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            },
            "briefTitle": "Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers",
            "officialTitle": "Tumor Microenvironment Features of Response to Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "perioperative-gemcitabine-cisplatin-and-pembrolizumab-in-potentially-resectable-biliary-tract-cancers"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-08",
            "studyFirstSubmitQcDate": "2023-08-16",
            "studyFirstPostDateStruct": {
                "date": "2023-08-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Merck Sharp & Dohme LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic responses."
        },
        "conditionsModule": {
            "conditions": [
                "Pancreatic Cancer"
            ],
            "keywords": [
                "Biliary Tract cancer",
                "Pembrolizumab",
                "Gemcitabine",
                "Cisplatin",
                "Immunotherapy",
                "Potentially resectable biliary tract cancer",
                "Anti PD-L1",
                "PD-L1",
                "Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 27,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Gemcitabine, Cisplatin and Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Gemcitabine",
                        "Drug: Cisplatin",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Gemcitabine",
                    "description": "Patients will receive treatment on Day 1 and Day 8 of each cycle. Gemcitabine (1000 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.",
                    "armGroupLabels": [
                        "Gemcitabine, Cisplatin and Pembrolizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cisplatin",
                    "description": "Patients will receive treatment on Day 1 and Day 8 of each cycle. Cisplatin (25 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.",
                    "armGroupLabels": [
                        "Gemcitabine, Cisplatin and Pembrolizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Patients will receive treatment on Day 1 of each cycle. Pembrolizumab (200 mg) will be administered IV on Day 1 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery. Pembrolizumab (400 mg) will be administered IV Q6 weeks up to 4 cycles as maintenance.",
                    "armGroupLabels": [
                        "Gemcitabine, Cisplatin and Pembrolizumab"
                    ],
                    "otherNames": [
                        "KEYTRUDA; anti-PD-1 mAb"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Average minimum Euclidean distance from CD8+ T cells to immunosuppressive tumor-associated macrophages (TAMs) at the per-cell level in patients with a major pathologic response versus pathologic non-responders.",
                    "description": "The evaluable population of this endpoint consist of all patients who receive at least one dose of study drug and have TAMs and CD8 T cell measures at the time of surgery. TAMs being evaluated are the following: immunosuppressive TAMs with high Arginase-1 expression (CD68+CD163+Arg-1hiPDL1-/+), immunosuppressive TAMs with low Arginase-1 expression (CD68+CD163+Arg-1lo PDL1-/+), and less immunosuppressive TAMs (CD68+CD163-HLA-DRhi/CD86hi/PDL1hi)",
                    "timeFrame": "4 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants experiencing grade 3 or above drug-related toxicities",
                    "description": "When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v5.0) will be counted only once for a given subject.",
                    "timeFrame": "4 years"
                },
                {
                    "measure": "Number of patients proceeding to surgery without an extended treatment-related delay as a measure of feasibility",
                    "description": "Extended treatment delay is defined as a delay of greater than 60 days of the pre-planned surgical evaluation date, or inability to go to surgery due to an adverse event related to study treatment.",
                    "timeFrame": "144 days"
                },
                {
                    "measure": "Major pathologic response rate",
                    "description": "The number of participants with a major pathologic response as defined by \u2264 10% residual viable tumor cells in the resection of the primary tumor and lymph nodes.",
                    "timeFrame": "8-12 weeks"
                },
                {
                    "measure": "R0 resection rate",
                    "description": "The number of participants with a R0 resection as defined by a microscopically margin-negative resection, in which no tumor (gross or microscopic) remains in the primary tumor bed.",
                    "timeFrame": "60 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Must have a newly diagnosed, biopsy-proven biliary tract cancer (BTC) including gallbladder, intrahepatic, extrahepatic, and hilar cholangiocarcinoma.\n* Resectable BTC (biliary tract cancer)\n* Measurable disease per RECIST 1.1 as determined by the investigator.\n* Age \u226518 years.\n* ECOG (Eastern Cooperative Oncology Group) performance status \u22641 or Karnofsky \u226580\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests.\n* Patients must have adequate liver function defined by study-specified laboratory tests.\n* Patients with chronic or acute HBV or HCV infection must have disease controlled prior to enrollment.\n* Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test.\n* For both Women and Men, must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Receiving, or previously received, any systemic chemotherapy, or investigational agent for BTC.\n* Has received prior radiotherapy within 2 weeks of start of study intervention.\n* Patients with a history of prior treatment with anti-PD-1 and anti-PD-L1.\n* Have been diagnosed with another cancer or myeloproliferative disorder whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this study's investigational drugs.\n* Has a known history of Human Immunodeficiency Virus (HIV)/AIDS\n* Has active co-infection with HBV and HDV.\n* Has a diagnosis of immunodeficiency.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years.\n* Systemic or topical corticosteroids at immunosuppressive doses.\n* Prior allogeneic stem cell transplantation or organ transplantation.\n* Prior tissue or organ allograft or allogeneic bone marrow transplantation, including corneal transplants.\n* Uncontrolled intercurrent active medical and/or psychiatric illness/social psychosocial problems that that would limit compliance with study requirements.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Evidence of clinical ascites.\n* Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.\n* Previously identified allergy or hypersensitivity to monoclonal antibodies or any component of the study treatment formulations.\n* Pregnant or breastfeeding.\n* WOCBP and men with female partners (WOCBP) who are not willing to use contraception.\n* Subjects unable to undergo venipuncture and/or tolerate venous access.\n* Patient is at the time of signing informed consent a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Colleen Apostal, RN",
                    "role": "CONTACT",
                    "phone": "410-614-3644",
                    "email": "GIClinicalTrials@jhmi.edu"
                },
                {
                    "name": "Joann Santmyer, RN",
                    "role": "CONTACT",
                    "phone": "410-614-3644",
                    "email": "GIClinicalTrials@jhmi.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Marina Baretti, M.D.",
                    "affiliation": "SKCCC Johns Hopkins Medical Institution",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "SKCCC Johns Hopkins",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21231",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Colleen Apostol, RN",
                            "role": "CONTACT",
                            "phone": "410-614-3644",
                            "email": "GIClinicalTrials@jhmi.edu"
                        },
                        {
                            "name": "Joann Santmyer, RN",
                            "role": "CONTACT",
                            "phone": "410-614-3644",
                            "email": "GIClinicalTrials@jhmi.edu"
                        },
                        {
                            "name": "Marina Baretti, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001661",
                    "term": "Biliary Tract Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000001660",
                    "term": "Biliary Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M4947",
                    "name": "Biliary Tract Neoplasms",
                    "asFound": "Biliary Tract Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4946",
                    "name": "Biliary Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T761",
                    "name": "Biliary Tract Cancer",
                    "asFound": "Biliary Tract Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M6182",
                    "name": "Cisplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}